Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Profit After Tax (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Profit After Tax for 11 consecutive years, with -$95.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 25.69% to -$95.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$412.7 million, a 20.49% increase, with the full-year FY2025 number at -$412.7 million, up 20.49% from a year prior.
  • Profit After Tax was -$95.8 million for Q4 2025 at Intellia Therapeutics, up from -$101.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$46.2 million in Q1 2021 to a low of -$147.0 million in Q2 2024.
  • A 5-year average of -$107.7 million and a median of -$110.3 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 217.87% in 2022, then soared 31.11% in 2025.
  • Intellia Therapeutics' Profit After Tax stood at -$81.2 million in 2021, then crashed by 39.6% to -$113.4 million in 2022, then decreased by 16.54% to -$132.2 million in 2023, then rose by 2.47% to -$128.9 million in 2024, then grew by 25.69% to -$95.8 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Profit After Tax are -$95.8 million (Q4 2025), -$101.3 million (Q3 2025), and -$101.3 million (Q2 2025).